Written by David and verified by Ionis Following the recent announcement by Ionis about the clinical trial at
Charlie is one of the children taking part in the Natural Evolution Study (NHS) conducted by Ionis Pharmaceuticals in the United States. The study has
In February 2024, David Covini, President of DupMECP2, visited the biotech company HuidaGene Therapeutics in Shanghai. This visit
A revolutionary technology with high potential in MECP2 gene duplication syndrome The world of genetic engineering has
Huidagene Therapeutics is a biotechnology company based in Shanghai and New Jersey, focusing on the
The world of healthcare can often seem complex, especially when it comes to understanding the different systems and studies involved.
On 28 October, members of our team: Ana (member of the Board of Directors), Caroline (member of the Board of Directors, Vice-President),
Exactly one year ago, the "Lasst uns MDS heilen - DupMECP2" association was founded. The history of the association
10 March 2023 marks a very important date for the rare disease community. Trofinetide has been approved
MECP2 duplication syndrome (MDS) is a rare and progressive neurogenetic disorder affecting children. It is caused by
English (UK) 
Français 
Deutsch 
Español 
Italiano 
Ελληνικά 
Polski